Report overview
Cell and gene therapy drug delivery industry is a transformative industry whose full potential is only just beginning to emerge. Cell and gene therapy involves the extraction of cells, protein, or genetic material (DNA) from the donor, and altering them to provide highly personalized therapy. Cell and gene therapies may offer longer-lasting effects than traditional medicines. One of the significant drugs of the cell and gene therapy industry is CAR-T cell-based medicines, which include both cell therapy and gene therapy. Various market players are actively investing in the research and development of the cell and gene therapy industry. The players are offering improved and new products, which meet the critical needs of patients.
This report aims to provide a comprehensive presentation of the global market for Cell and Gene Therapy Drug Delivery Devices, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Gene Therapy Drug Delivery Devices. This report contains market size and forecasts of Cell and Gene Therapy Drug Delivery Devices in global, including the following market information:
Global Cell and Gene Therapy Drug Delivery Devices Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Cell and Gene Therapy Drug Delivery Devices market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Sterile Insulin Syringe Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cell and Gene Therapy Drug Delivery Devices include Amgen, Inc., Bausch and Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute and Kite Pharma, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Cell and Gene Therapy Drug Delivery Devices companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cell and Gene Therapy Drug Delivery Devices Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Cell and Gene Therapy Drug Delivery Devices Market Segment Percentages, by Type, 2022 (%)
Sterile Insulin Syringe
Pre-Filled Syringe
Infusion Bags
Global Cell and Gene Therapy Drug Delivery Devices Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Cell and Gene Therapy Drug Delivery Devices Market Segment Percentages, by Application, 2022 (%)
Luxturna
Kymriah
Provenge
Zolgensma
Yescarta
Strimvelis
Global Cell and Gene Therapy Drug Delivery Devices Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Cell and Gene Therapy Drug Delivery Devices Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cell and Gene Therapy Drug Delivery Devices revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Cell and Gene Therapy Drug Delivery Devices revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen, Inc.
Bausch and Lomb Incorporated
Becton, Dickinson and Company
Bluebird bio, Inc.
Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
Dendreon Pharmaceuticals LLC.
Helixmith Co., Ltd (ViroMed Co., Ltd)
Human Stem Cell Institute
Kite Pharma, Inc.
Kolon Tissue Gene, inc.
Novartis AG
Orchard Therapeutics plc.
Pfizer, Inc.
Renova Therapeutics
Spark Therapeutics, Inc.
uniQure N.V.
Vericel Corporation
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cell and Gene Therapy Drug Delivery Devices, market overview.
Chapter 2: Global Cell and Gene Therapy Drug Delivery Devices market size in revenue.
Chapter 3: Detailed analysis of Cell and Gene Therapy Drug Delivery Devices company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cell and Gene Therapy Drug Delivery Devices in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
